1-7 of 7
Corinne Reimer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L. Dale, Scott Boiko, Tony Cheung, Jingwen Zhang, Shenghua Wen, Lillian Castriotta, Deborah Lawson, Michael Collins, Larry Bao, Miika J. Ahdesmaki, Graeme Walker, Greg O'Connor, Tammie C. Yeh, Alfred A. Rabow, Jonathan R. Dry, Corinne Reimer, Paul Lyne, Gordon B. Mills, Stephen E. Fawell, Michael J. Waring, Michael Zinda, Edwin Clark, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2563–2574.
https://doi.org/10.1158/1535-7163.MCT-16-0141
Published: 01 November 2016
View articletitled, AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Open the PDF for AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract B112: Synergistic anti-lymphoma activity of ibrutinib and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma is maintained in vivo on an intermittent schedule

Theresa Proia, Nanhua Deng, Urzsula Polanska, Deborah Lawson, Vasu Sah, Maryann San Martin, Corinne Reimer, Sabina Cosulich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B112.
https://doi.org/10.1158/1535-7163.TARG-15-B112
Published: 01 December 2015
View articletitled, Abstract B112: Synergistic anti-lymphoma activity of ibrutinib and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma is maintained in vivo on an intermittent schedule
Journal Articles

Abstract A94: STAT3 antisense treatment decreases M2 macrophage infiltration and enhances the activity of checkpoint inhibitors in preclinical tumor models

Richard D. Woessner, Patricia McCoon, Shaun Grosskurth, Paul Lyne, Kirsten Bell, Mike Collins, Nanhua Deng, Rachel DuPont, Michele Johnstone, Youngsoo Kim, Deborah Lawson, Robert MacLeod, Lourdes Pablo, Corinne Reimer, Vasu Sah, Margaret Veldman-Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A94.
https://doi.org/10.1158/1535-7163.TARG-15-A94
Published: 01 December 2015
View articletitled, Abstract A94: STAT3 antisense treatment decreases M2 macrophage infiltration and enhances the activity of checkpoint inhibitors in preclinical tumor models
Journal Articles

Abstract A12: Small molecule inhibitor of BCL2 in combination with RCHOP is effective in CD20 negative DLBCL.

Chaitali Dutta, Michele Mayo, Mike Collins, Christopher Brueckner, Deborah Lawson, Zhongwu Lai, Larry Bao, Corinne Reimer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A12.
https://doi.org/10.1158/1535-7163.TARG-13-A12
Published: 01 November 2013
View articletitled, Abstract A12: Small molecule inhibitor of BCL2 in combination with RCHOP is effective in CD20 negative DLBCL.
Journal Articles

Abstract A221: Novel PARP6 inhibitors demonstrate in vivo efficacy in xenograft models.

Michele F. Mayo, Shaun Grosskurth, Xin Wang, Philip Petteruti, Prasad Nadella, Corinne Reimer, Keith Mikule
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A221.
https://doi.org/10.1158/1535-7163.TARG-13-A221
Published: 01 November 2013
View articletitled, Abstract A221: Novel PARP6 inhibitors demonstrate in vivo efficacy in xenograft models.
Journal Articles

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 145–156.
https://doi.org/10.1158/1535-7163.MCT-09-0554
Published: 12 January 2010
View articletitled, A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Open the PDF for A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Biological characterization of MLN944: A potent DNA binding agent

Darshan S. Sappal, A. Kathleen McClendon, James A. Fleming, Vala Thoroddsen, Kelly Connolly, Corinne Reimer, Ronald K. Blackman, Christine E. Bulawa, Neil Osheroff, Peter Charlton, Laura A. Rudolph-Owen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (1): 47–58.
https://doi.org/10.1158/1535-7163.47.3.1
Published: 28 January 2004
View articletitled, Biological characterization of MLN944: A potent DNA binding agent
Open the PDF for Biological characterization of MLN944: A potent DNA binding agent in another window